AVTR

Avantor Inc
NYSEHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES

Key Statistics

Market Cap
$6.96B
P/E Ratio
EPS
$-0.80
Beta
0.94
52W High
$15.93
52W Low
$7.26
50-Day MA
$8.89
200-Day MA
$10.36
Dividend Yield
Profit Margin
-8.42%
Forward P/E
13.14
PEG Ratio

About Avantor Inc

Avantor, Inc. provides products and services to clients in the biopharmaceutical, healthcare, education and government, advanced technologies and applied materials industries in America, Europe, Asia, the Middle East and Africa. The company is headquartered in Radnor, Pennsylvania.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$6.55B
Gross Profit (TTM)$2.11B
EBITDA$948.10M
Operating Margin6.26%
Return on Equity-9.44%
Return on Assets2.78%
Revenue/Share (TTM)$9.65
Book Value$8.26
Price-to-Book1.26
Price-to-Sales (TTM)1.06
EV/Revenue1.615
EV/EBITDA92.43
Quarterly Earnings Growth (YoY)-33.30%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$682.75M
Float$664.28M
% Insiders1.49%
% Institutions101.58%

Historical Volatility

HV 10-Day
43.10%
HV 20-Day
38.29%
HV 30-Day
47.41%
HV 60-Day
44.28%
HV Rank
52.4%

Volatility is currently contracting

Analyst Ratings

Consensus ($9.94 target)
3
Buy
11
Hold
2
Sell
1
Strong Sell

Latest News

Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026

RADNOR, Pa., July 1, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, and will hold a conference call to discuss the results on the same day at 8:00 a.m.

PRNewsWire7/1/2026Neutral
Avantor Q1 2026 Earnings Review: Stabilization Emerging, But Recovery Not Yet Visible

Avantor, Inc. reported a slight beat on 1Q26 EPS and revenue, but underlying organic growth and margins remain under pressure. Negative organic growth, margin compression, and subdued cash flow signal only early stabilization, not a confirmed recovery, especially in the VWR segment. Management reaffirmed 2026 guidance and expects sequential improvement, but the recovery is execution-dependent and gradual, with margins likely to remain below historical peaks.

Seeking Alpha4/30/2026Neutral
Avantor® Reports First Quarter 2026 Results

Net sales of $1,581 million Net income of $43 million; Adjusted EBITDA of $219 million Diluted GAAP EPS of $0.06; adjusted EPS of $0.17 Operating cash flow of $59 million; free cash flow of $25 million Reaffirms FY 2026 guidance RADNOR, Pa., April 29, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal quarter ended March 31, 2026.

PRNewsWire4/29/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026